Cargando…
Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study
BACKGROUND AND PURPOSE: The aim was to assess the safety and efficacy of nusinersen in adult 5q spinal muscular atrophy (SMA) patients. METHODS: Patients older than 15 years and followed for at least 6 months with one motor scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Lim...
Autores principales: | Vázquez‐Costa, Juan F., Povedano, Mónica, Nascimiento‐Osorio, Andrés E., Moreno Escribano, Antonio, Kapetanovic Garcia, Solange, Dominguez, Raul, Exposito, Jessica M., González, Laura, Marco, Carla, Medina Castillo, Julita, Muelas, Nuria, Natera de Benito, Daniel, Ñungo Garzón, Nancy Carolina, Pitarch Castellano, Inmaculada, Sevilla, Teresa, Hervás, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796289/ https://www.ncbi.nlm.nih.gov/pubmed/35872571 http://dx.doi.org/10.1111/ene.15501 |
Ejemplares similares
-
Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy
por: Vázquez‐Costa, Juan F., et al.
Publicado: (2022) -
Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen
por: Trifunov, Selena, et al.
Publicado: (2023) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018) -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021) -
Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)